Breast Cancer Clinical Trial
— DEFACTO2Official title:
Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology
Benefits of physical activity (PA) as supportive care in cancer have been widely demonstrated by the scientific community. However, survivors who have completed chemo-radio-immunotherapy treatments doesn't achieve PA recommendations on average. This reinforces the need to identify factors influencing PA level, and to propose a multilevel model (macro-, meso-, micro-level) to understand better what facilitates the adoption and maintenance of active behaviour and what hinders it. To date, there is no ecological model in France explaining this behaviour in the post-treatment phase of breast, colorectal, prostate, and lung cancers. From this initial model, we seek to design an educational and motivational intervention in PA. Thus, the investigators propose to test the feasibility of implementing an individualized program to increase and maintain level of physical activity and to decrease sedentary behaviours in physically inactive cancer survivors. This program is based through and identification of barriers and facilitators of an active lifestyle among this population.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 2023 |
Est. primary completion date | July 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - 18 years = age < 75 years - survivors of primary non-metastatic breast, lung, prostate or colorectal cancer (stage I, II or III and primary, second and relapse included) - 3 weeks to 20 years post-treatment (surgery, chemotherapy, radiation therapy and/or immunotherapy) not including hormonal therapy - Whose ability to participate in the APA intervention has been certified by a medical certificate issued by physician - Availability and willingness to invest in the DEFACTO study during the program (3 months) and during the post-program follow-up (12 months) - Participating, on average, in no more than 150 minutes of moderate physical activity or no more than 75 minutes of vigorous activity per week - Average at least 6 hours a day of sedentary behaviours - Able to read, understand and complete questionnaires in French - Able to use connected device (Vivosmart4®) and to perform simple operating actions (press a button, recharge the battery) - possessing a smartphone which can download Garmin Connect application ® - Able to walk unassisted - French speaking and living in France - having signed the consent form Exclusion Criteria: - Current evidence of metastatic disease - Having an absolute contraindication by a physician to practice PA - Using treatments that influence blood pressure, cardiotoxic drugs, painkillers (morphinics); - Using cane or walking aid - Deprived of liberty by judicial or administrative decision - Person under guardianship or curatorship - Pregnancy and/or lactating women - Being diagnosed of any cardiac abnormalities |
Country | Name | City | State |
---|---|---|---|
France | Laboratoire Educations et Promotion de la Santé UR3412 | Bobigny |
Lead Sponsor | Collaborator |
---|---|
Université Sorbonne Paris Nord | Garmin International, Ligue contre le cancer, France, Stimulab |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Weight | in kilograms (weight and height will be combined to report BMI in kg/m^2) | At Baseline (at inclusion) | |
Other | Height | in centimeters (height and weight will be combined to report BMI in kg/m^2) | At Baseline (at inclusion) | |
Other | Date of cancer diagnosis | (month/year) | At Baseline (at inclusion) | |
Other | Tumor location and cancer recurrence or second primary cancer | (breast, colorectal, lung or prostate) | At Baseline (at inclusion) | |
Other | Stage of cancer | (I, /II, or /III) | At Baseline (at inclusion) | |
Other | Type of treatment | (chemotherapy, radiation therapy, immunotherapy, hormonotherapy) | At Baseline (at inclusion) | |
Other | Clinical data | Body Mass Index (BMI, kg/m^2), date of diagnosis (month/year), tumour location (breast, colorectal, lung or prostate), stage of cancer (I, /II, or /III), cancer recurrence or second primary cancer, type of treatment, date on the treatment end (chemotherapy, radiation therapy, immunotherapy, hormonotherapy + month/year); (close-ended questions) | At Baseline (at inclusion) | |
Other | Date on the treatment end | (month/year) | At Baseline (at inclusion) | |
Other | Socio-demographic variables | Educational qualifications, economic class-status, current professional situation, household type, habitat type, geographical environment (rural or /urban); (close-ended questions) | At Baseline (at inclusion) | |
Primary | Change of physical activity (connected device) | Average daily steps, distance traveled, floors climbed, heart rate, cumulative duration of activities of moderate and vigorous intensities using VIVOSMART4® (Garmin) | One week before initiation of DEFACTO intervention, during the intervention and intervention at Month 3 and Month 6 and Month 12 | |
Secondary | Change of physical activity by the Global Physical Activity Questionnaire (GPAQ) | Change of physical activity evaluated by the GPAQ questionnaire, at baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | At baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | |
Secondary | Assessment of life quality | Assessment by using the Short-Form 12 questionnaire (SF-12) Life quality scores calculation | At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | |
Secondary | Assessment of Health literacy level | Assessment by using a single question concerning the need to resort refer to a health professional to understand health information | At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | |
Secondary | Assessment of Knowledge about PA and its link with cancer | Assessment by using specific questions of the Cancer Exercise Stereotypes Scale | At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | |
Secondary | Physical activity barriers | Assessment by using the "General determinants of PA" questionnaire. This tool examines 7 areas: 1) Lack of time; 2) Social influences; 3) Lack of energy; 4) Lack of willingness; 5) Fear of hurting yourself; 6) Lack of skill sets; 7) Lack of resources | At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | |
Secondary | Transtheorical model's variables related to physical activity | Assessment by using the "Stages of change" questionnaire, "Processes of change (POC)" questionnaire, "decisional balance" questionnaire, and "self-efficacy" questionnaire. | At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) | |
Secondary | Motivation to physical activity pratice | Types of motivation based on self-determination theory, assessment by using the Motivation Scale for by Physical Activity for Health Purposes | At Baseline (at inclusion), and at the completion of intervention (12 weekends after the start of the intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |